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Michael S. Roberts1,5 & Mark A. F. Kendall6
Microscale medical devices are being developed for targeted skin delivery of vaccines and the extraction 
of biomarkers, with the potential to revolutionise healthcare in both developing and developed 
countries. The effective clinical development of these devices is dependent on understanding the 
macro-molecular diffusion properties of skin. We hypothesised that diffusion varied according to 
specific skin layers. Using three different molecular weights of rhodamine dextran (RD) (MW of 70, 
500 and 2000 kDa) relevant to the vaccine and therapeutic scales, we deposited molecules to a range 
of depths (0–300 µm) in ex vivo human skin using the Nanopatch device. We observed significant 
dissipation of RD as diffusion with 70 and 500 kDa within the 30 min timeframe, which varied with MW 
and skin layer. Using multiphoton microscopy, image analysis and a Fick’s law analysis with 2D cartesian 
and axisymmetric cylindrical coordinates, we reported experimental trends of epidermal and dermal 
diffusivity values ranging from 1–8 µm2 s−1 to 1–20 µm2 s−1 respectively, with a significant decrease in 
the dermal-epidermal junction of 0.7–3 µm2 s−1. In breaching the stratum corneum (SC) and dermal-
epidermal junction barriers, we have demonstrated practical application, delivery and targeting of 
macromolecules to both epidermal and dermal antigen presenting cells, providing a sound knowledge 
base for future development of skin-targeting clinical technologies in humans.
The skin has long been employed as a route for the delivery of bioactive molecules for local and systemic effects, 
and more recently, a route for the detection of analytes1, with the particular advantage of avoiding hepatic 
first-pass metabolism. The stratum corneum (SC) is considered to be the main barrier to penetration of actives2 
and the removal of analytes. The underlying strata, the viable epidermis (VE) and the dermis are often the main 
targets of the compounds delivered through the skin for local and systemic delivery, as well as the detection of 
circulatory biomarkers. Whilst there are now a number of topical and transdermal products on the market3, there 
are many actives which do not readily permeate the SC. Much research in the field of skin delivery has now been 
devoted to the development of strategies to overcome the SC barrier and enhance topical and transdermal pen-
etration for poorly permeating actives. The principal solutions to the enhancement of percutaneous absorption 
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involve chemical methods, such as the use of penetration enhancers, and physical methods such as iontophoresis, 
sonophoresis and electroporation4–7.
In the past several decades, there has been considerable interest in the development of nanotechnologies 
for improved topical and transdermal delivery. These include formulation-based nanosystems, such as colloidal 
nanocarrier systems (nanoemulsions, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs)), 
flexible nanovesicles: elastic liposomes, transfersomes, ethosomes and niosomes, and microdevices involving 
microneedle-based technologies8–11. The latter physically and mechanically overcomes the SC to deliver actives 
directly to the VE and dermis. A wide range of pharmaceutical formulations, with varied purposes and molecu-
lar weights (MWs), have been delivered using microneedles, including naltrexone12,13, verapamil, amlodipine14, 
plasmid DNA15, cosmeceutical peptides (melanostatin, rigin and pal-KTTKS)16, insulin17,18 and macromolecules 
such as human growth hormone19 and vaccines20–23. Microneedle, skin-targeted devices have also been used to 
extract biomarkers for disease diagnostic applications in influenza24 and dengue25, providing a new and rapid way 
of detection without the need to draw blood from patients.
Vaccines are now mainly given by injection into intramuscular and subcutaneous tissues. The skin provides an 
ideal alternative and shallower delivery target as it is capable of producing an effective immune response mediated 
by antigen presenting cells (APCs) found in the Langerhans cells in the VE and dendritic cells and macrophages 
in the dermis26. In contrast, needles and syringes lack the precision to target the APCs that are within the micro-
metre range from the surface of the skin, instead delivering vaccines into immunologically-poor regions of the 
body (i.e. muscle). We have recently demonstrated that targeting the skin’s immune system with the Nanopatch 
technology produced a more efficient immune response with 1/100th of the dose usually administered intramus-
cularly, and also avoided the pain and discomfort associated with traditional methods of vaccine delivery27,28.
Given the enormous potential29 of nano-delivered vaccines in both the developed and developing world, 
namely vaccine thermostability, reduced costs and elimination of sharps injury and possible self-administration, 
it is imperative to understand the diffusion of the macromolecules in the skin after administration to predict their 
availability for uptake by cells in proximity. This will also provide sound knowledge on the ability to extract ana-
lytes from the skin, for them to diffuse near capture surfaces. We have shown that solute diffusion is dependent on 
MW and differs in the individual layers of the skin, which possess distinct mechanical and structural properties 
for both small solutes30; local deep tissue penetration of compounds after dermal application: structure-tissue 
penetration relationships30; molecular size as the main determinant of solute maximum flux across skin31. and, 
in mice, macromolecules, where diffusion gradually increased as the depth from the skin surface increased32. 
We have reported significant differences between mice and human skin in small solute permeability33 and in the 
stiffness of the skin34, it is expected the diffusion kinetics of macromolecules in the VE and dermis would also 
vary between the two species.
The primary barrier to effective skin delivery of solutes is the highly-ordered lipid-rich region of the Stratum 
Corneum (SC). Microneedle devices overcome this barrier by piercing the SC to enable direct deposition of their 
cargo and its extraction within the epidermis and the dermis. However, for effective delivery, this deposited vac-
cine/drug or extracted biomarkers must diffuse through the surrounding tissues to reach their target sites.
The permeability of various solutes have been investigated in various animal skin models, such as rodent32 
and porcine skin35, as potential surrogates for human skin and shown to possess different permeabilities33,36, skin 
structures, composition and mechanical behaviour34 from human skin. However, how macromolecule solute 
diffusivity in each layer relates to the underlying skin morphology is not well defined and this knowledge is of 
importance in further developing various human skin delivery devices using animal skin findings.
Several studies have reported a range of diffusion coefficients for macromolecules in animal and human skin. 
Raphael et al. studied the diffusion of 70 kDa and 2 MDa RD in mouse skin, and reported diffusion coefficients 
highly dependent on skin layers, in32. Römgens et al. reported a similar diffusivity for 500 kDa fluorescein labelled 
dextran in the epidermis (8 µm2 s−1) in the dermis (9 µm2 s−1) and a somewhat higher diffusivity (23 µm2 s−1) for 
a 40 kDa macromolecule diffusion in human skin using fluorescence recovery after photobleaching (FRAP)36. 
Mansoor et al. reported that microneedle delivery of doxorubicin (~580 Da) in pig dermis was associated with a 
doxorubicin diffusivity of approximately 0.5–4.2 µm2 s−135.
Here, we investigated the diffusion properties of macromolecules in every stratum of the human skin (see 
schematic Fig. 1(a)) after the application of a Nanopatch, an ultra-high density microneedle array vaccine delivery 
patch. This included the dermal-epidermal junction, a region that hinders diffusion of both lipophilic and hydro-
philic compounds into the dermis. The diffusion resistance is due to the tight adherence of stratum basale (SB) 
cells through tight junctions, desmosomes and linker proteins, and the densely packed dermal collagen invag-
inations of papillary dermal cells37,38, that act as a physical barrier for large molecules39. This contrasts with the 
loosely arranged collagen matrix found in the deeper dermis that provides less structural resistance than the epi-
dermis to diffusion to target cells within the region. In this study, we disrupted both the SC and dermal-epidermal 
barriers physically for macromolecule delivery.
Typical sizes of vaccines can range from ~14 kDa40, ~70 kDa41 to ~100 kDa42, and even in the megadalton 
range for DNA plasmid vaccines43 with 1000 s of base pairs (bp), with one bp ~650 Da. For example, influenza 
vaccine proteins, namely haemagglutinin and neuraminidase, have a MW of ~77 kDa and ~60 kDa respectively44 
although these proteins typically exist as polymers, weighing ~230–240 kDa, with some reported to be in the 
order of ~670 kDa45. We used rhodamine-labelled dextrans (RD) as a model for large molecules being delivered 
into the skin. We selected 70, 500 and 2000 kDa to represent the low, intermediate and high vaccine MWs. The 
RDs were delivered into ex vivo human skin with the Nanopatch and their diffusion was imaged over time using 
high-resolution multiphoton microscopy (MPM). The acquired images were then processed to calculate the diffu-
sivity of these macromolecules in every imaged skin strata. This understanding of the diffusion properties of rele-
vant molecular sizes in human skin will be crucial for vaccine and drug delivery in translational clinical research.
www.nature.com/scientificreports/
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Results
In this paper, we have first characterised the Nanopatch microprojections used in the experiments shown in 
Section 2.1. We then used a maximum and minimum threshold analysis to provide a visual illustration on where 
the dye was found in space and time. The maximum and minimum concentrations of the diffusion fronts show 
Figure 1. (a) Schematic illustrating one Nanopatch microprojection applied into the skin with the diffusion of RD 
within the different layers of human skin. (b) Allocation of coordinates (three z-planes shown) for analysis, where 
RD intensities are recorded along each circumference of 5 µm, in radial increments up to the midpoint between 
two projections, with a depth spacing of 5 µm as well, from the skin surface down to 100 µm. (c) A schematic 
example of extracted intensity values from the centre of puncture hole with SD in one layer and at one time point.
www.nature.com/scientificreports/
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how they reduce and clear out over time, presented in Section 2.2. Finally, the third major results of this work in 
Section 2.3 presents the diffusion coefficient analysed with Fick’s second law (enabling comparison with many 
diffusion studies), which interprets the subtle differences between the neighbouring (in both space and time) 
pixel values, rather than at the two extreme thresholds. In this case, we used the coefficient to highlight the local 
reduction in the dermal-epidermal junction region.
Penetration of the Nanopatch into ex vivo human skin. Figure 2 illustrates an SEM image of a 
Nanopatch prototype diced into a 4 × 4 mm square (a) and the uncoated projections in (b), and coated projections 
prior to skin administration (c) and removed approximately halfway down the projection shafts after adminis-
tration (d). This demonstrates the deposition of the coating formulation from the projections to the skin. Several 
corneocytes detached from the SC were also observed stuck onto the microprojections as indicated by the arrows. 
Penetration depths of the microprojections into full thickness skin and dermatomed dermis were measured at 
least 100 times as 149 ± 49 µm and 128 ± 40 µm respectively. The amount of formulation deposited into the skin 
was quantified as 30.6 ± 5.05% of total amount coated onto the microprojections. Figure 3 displays cryo-SEM 
images of patched skin with the Nanopatch remaining in the skin. The SC, VE and dermis were distinguished, as 
indicated in (b).
Assessment of rhodamine dextran diffusion and clearance. Representative images of the patched 
skin at selected time points and depths are displayed in Fig. 4(a–c), demonstrating the successful delivery of 70, 
500, 2000 kDa RD to a minimum depth of 100 µm in human skin ex vivo. Each RD MW deposited showed sim-
ilar diffusion patterns. Significant deposition of all RD coatings was observed on the skin surface. Some coating 
was also collected in the furrows, as shown in the images of the VE (10–40 µm in depth). The patched areas were 
clearly identifiable as circular, regular spots in each stratum. A complete representative stack, inclusive of all time 
points and depths in videos is available in the Supplementary Figs S1–S4.
Upon closer observation of Fig. 4, diffusion fronts were separated into two distinct regions from the centre of 
the microprojection holes. An intense and fully saturated region that was separable for analysis as a distinct area 
when a 5% threshold was employed, corresponds to a very high concentration of RD, likely was in direct contact 
or very close to microprojections during the initial payload deposition. We also observed a larger, outer region, 
(a) (b)
(c) (d)
Figure 2. (a) Photograph of a 4 × 4 mm Nanopatch held with tweezers in front of a Nanopatch wafer. (b) 
Representative image of secondary electron (SE) detector SEM of uncoated Nanopatch projections at a 
45° tilt. (c) Representative image of backscatter electron (BSE) detector SEM of a coated Nanopatch. (d) 
Representative BSE detector SEM of a coated Nanopatch applied on full thickness ex vivo human skin and 
removed. (i) Dissolved coating representing the extent of skin penetration, and (ii) skin fragments lodged on 
microprojections are indicated as shown. Images shown in (a–d) are different patches but from the same wafer.
www.nature.com/scientificreports/
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captured with a 95% threshold, corresponding to the minimum detectable fluorescence diffusion front. This was 
denoted as the farthest distance the molecule has spread. Release profiles (diffusion fronts) of both maximum 
and minimum saturation for 70, 500 and 2000 kDa in human skin ex vivo over 30 minutes (Fig. 5), showed that 
the molecules dissipated (i.e. mean diffusion front radius decreased) over time at each location. This represented 
molecular diffusion of concentrations to below detectable thresholds. In terms of depth, all RDs appeared to 
increase in the spread from the surface, peaking at approximately the SC-VE boundary.
The rate of dissipation was quantified using Fig. 5 as the mean change in radius over time for each skin layer 
(Table 1) using the maximum intensity threshold radius observed. The times show an estimation of the mean 
duration for each layer the radius would reduce to zero. These values were found to be proportional to the MW 
and increased from the SC to VE. However, a reduction in the clearance rate was estimated for regions towards 
the dermis. No clearance information was available for 70 kDa RD at deep layers, likely due to rapid clearance of 
diffusion fronts prior to imaging, in contrast to stagnation of 2000 kDa RD.
Experimentally derived diffusivity values by intensity profiling. Diffusion data was calculated as 
a quantifiable value by comparing intensities of each pixel along multiple concentric radii from the projection 
centre (Fig. 6). An inverse proportionality between MW and diffusivity can be observed. The 2 MDa RD appeared 
to have slightly higher diffusivity values than 500 kDa, although within error. All three MWs demonstrated diffu-
sivity coefficients in the same order of magnitude, and because of this, the deeper skin layers were subsequently 
investigated directly using the 500 kDa RD. Two models are presented – in 2D cartesian and axisymmetric cylin-
drical coordinates. Both results are closely related to each other, although the cartesian coordinate modelling 
appeared to have continually increasing diffusivity in the dermis, in contrast to the cylindrical model, which 
appeared flatter. Nevertheless, both models illustrate a local reduction in the dermal-epidermal junction region. 
The SC diffusivity of the three MWs was ~1–5 µm2 s−1. Diffusivity doubled from the SC to the VE, to approxi-
mately ~2–10 µm2 s−1 in the case of the cartesian model, and slightly less at ~2–3 µm2 s−1 in the cylindrical model. 
Both reduced again to the lowest values in the dermal-epidermal junction at ~0.7–3 µm2 s−1. Diffusivity increased 
again past the dermal-epidermal junction and continued to rise to the highest point in the reticular dermis at an 
average of 10–20 µm2 s−1, and remained at approximately 1–3 µm2 s−1 in the cylindrical model.
Discussion
In this work, we have shown direct deposition of fluorescence-labelled, macromolecules with a range of 
MWs into the epidermal and dermal regions of human skin, overcoming the barrier effects of the SC and the 
dermal-epidermal junction by using a Nanopatch device (microneedle array drug delivery patch). The micro-
projections of the Nanopatch physically disrupted the SC and the dermal-epidermal junction to overcome these 
barriers to epidermal and dermal delivery. Macromolecules were then delivered to the viable epidermis and the 
dermis, where APCs critical for immune response reside (i.e. VE – Langerhans cells; dermis – dermal dendritic 
cells)27. In comparison, needles used for intradermal injections are too large to target APCs accurately. The sub-
sequent macromolecule diffusion within the skin strata demonstrated, quantified and modelled allows the pre-
diction of transport to target sites within the skin, including to the microcirculation for transdermal delivery. The 
data was collected using non-invasive MPM from all layers of skin and analysed using efficient yet straightfor-
ward modelling tools. Apart from a few in vivo studies46, our work, using ex vivo human skin and its application 
delivery method, is the closest model representing clinical and real-life conditions, which is highly valuable in 
demonstrating the potential for novel skin-based vaccine delivery. This work will inform the development of a 
wide range of nano- and micro-technology based skin delivery systems for macromolecules.
The SC is widely accepted to be the primary barrier to penetration of any topically applied compound larger 
than 500 Da to the skin47. We have identified first that the dermal-epidermal junction provides a second barrier 
to diffusion of molecules both in the drug and vaccine size range. The decreased diffusivity values measured at 
the two barriers (SC and dermal-epidermal junction), relative to the VE and dermis (approximately one order of 
magnitude difference) is likely associated with the unique morphology and organisation of the barrier regions34. 
(a) (b)
Figure 3. (a,b) Representative Cryo-SEM images of transverse-fractured ex vivo human skin with Nanopatch 
applied to the skin. The microprojection, stratum corneum (SC), viable epidermis (VE) and dermis (D) were 
labelled on (b).
www.nature.com/scientificreports/
6Scientific RepoRtS |         (2018) 8:17759  | DOI:10.1038/s41598-018-36009-8
We suggest that the dermal-epidermal junction may be as formidable a barrier as the SC, as demonstrated by the 
reduction in lateral diffusion, even with microprojection intervention (Fig. 6), which is significantly higher than 
topically-applied formulations of similarly sized molecules32. We also believe that the dermal-epidermal junction 
Figure 4. Representative multiphoton images of ex vivo human skin at different depths at 5, 13, 23 and 
33 minutes post Nanopatch application onto the skin. The Nanopatch was coated with (a) 70 kDa (b) 500 kDa 
and (c) 2000 kDa rhodamine-labelled dextran, applied onto the skin using a spring-loaded applicator and left on 
the skin for 2 minutes to allow sufficient time for coating dissolution and approximately 3 minutes for excision 
and loading of the specimen onto the microscope stage and initialising it before the first images were captured. 
All images were pseudocoloured to highlight rhodamine-dextran (magenta) and skin (green) emissions.
www.nature.com/scientificreports/
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is likely to inhibit vertical diffusion of the RDs further. This supports the previous findings of Andrews et al. pro-
posed that the entire epidermis could limit transdermal delivery48. This is important, as the focus of the design 
of skin delivery systems for the past 40 years has been to overcome the SC, without the acknowledgement of this 
second barrier region.
Microprojection-based delivery systems provide unique advantages in transdermal delivery, as they breach 
the SC, epidermis and the dermal-epidermal junction. Here, the Nanopatch was placed in the skin for two min-
utes, an acceptable and representative administration protocol of a clinical scenario for immunisation delivery. 
We expect diffusivity to be even higher in the presence of blood circulation in an in vivo model, due to increased 
Figure 5. Mean RD clearance rate detected at 5% and 95% threshold for (a) 70 kDa, (b) 500 kDa and (c) 2 MDa. 
▲ = 5% threshold – 5 mins, ▼ = 5% threshold – 33 mins, ● = 95% threshold – 5 mins, ○ = 95% threshold – 
33 mins.
www.nature.com/scientificreports/
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movement of inter- and intracellular fluids; and we, therefore, speculate a further reduction of delivery timeframe 
compared to the mouse model32, while achieving similar delivery efficiencies. We also expect diffusivity to be 
approximately constant throughout the reticular dermis in the current ex vivo condition, given that its structure 
remains mostly homogenous through its full thickness, but it may be dependent on the addition of blood flow in 
the in vivo state49,50.
We also demonstrated clearance of RD from the skin layers, that had not been observed in the mouse model32. 
It is possible that the Nanopatch configured with larger microprojection geometry (250 µm versus 100 µm) and 
lower microprojection density (10,000 cm−1 versus 20,000 cm−1) in this study allowed sufficient amounts of RD 
to dissipate into the greater tissue volume, hence our observation of the diffusion fronts dissipating rather than 
spreading outwards from projection centres. This efflux diffused to concentrations below the detectable threshold 
over time. It is unlikely that the RD diffused against the concentration gradient to fully saturated projection cen-
tres (Fig. 5). This’dissipation’ effect was also observed by Mansoor et al. investigating doxorubicin concentrations 
in the VE of porcine skin models, a skin type that has more structural similarity to human skin in terms of skin 
layer thicknesses35 than mouse skin.
Although the diffusivity of 70 kDa RD was slightly higher than 500 and 2000 kDa RD (Fig. 6), they were well 
within the SD in the SC and VE (~1–5 µm2 s−1 and ~2–10 µm2 s−1 respectively). A marked reduction of diffusivity 
(~0.7–3 µm2 s−1) was observed in the dermal-epidermal junction. Diffusivity of 500 kDa RD was highest in the 
dermis (10–20 µm2 s−1, 2D cartesian model only). Regardless of model, these values highlight the importance 
of characterising diffusivity in each skin strata separately due to the dependency along the depth of the skin, 
cf. literature explored earlier reporting simplified or singular diffusion coefficients, suggesting a close correla-
tion between the ability of the compound to diffuse and the skin’s physical and mechanical characteristics (e.g. 
proportional to elasticity, and an inversely proportional to viscoelasticity)51. Secondly, provided in this paper 
are two models – 2D cartesian and axisymmetric cylindrical coordinates. The former was provided enabling 
direct comparison with Raphael et al.’s work32 illustrating a very similar rise-and-fall trend along the depth of 
the skin. However, an improvement to the accuracy of the modelling using cylindrical coordinates accounted 
for the expanding volume as the fluorescence progress farther outwards from the axis centre, saw discernible 
differences compared to the former model. While we believe this may be more accurate to analysis diffusion from 
microprojections, it does not provide definitive diffusion coefficients of the human skin. Nevertheless, it does, 
however, suggest that our results are sufficiently accurate, considering the inter- and intra-specimen variability 
in biological tissues.
While not explored in the scope, the partition coefficient P, measuring hydrophobicity or lypophilicity as log P 
may be as important as molecular weight. The hydrophobicity would depend on the formulation constituents: for 
example, hydrophilic: proteins, peptides, nucleic acids, carbohydrates, haptens, and hydrophobic: lipopeptides, 
antigens, adjuvants, linker molecules52. Given that cells and intercellular spaces are well-hydrated in the viable 
skin layers, a more hydrophilic formulation may exhibit higher diffusion rates than a hydrophobic formulation – 
and this should be explored as future work by applying the same diffusion model proposed here.
Layer/MW (kDa)
Time (min)
70 500 2000
Stratum corneum 42 61 65
Viable epidermis 31 37 67
Dermis n/a 25 124
Table 1. Time for fully saturated RD (5% threshold) to clear out in each skin layer from a microprojection site 
estimated using Fig. 5.
Figure 6. Diffusivity of RD in ex vivo human skin for 70 kDa, 500 kDa and 2 MDa. Curve fits are not 
continuous due to the analysis of separate stacks and truncation of layers lacking signal. Four replicates per 
molecule size. Error bars indicate SD. SC = stratum corneum, VE = viable epidermis, SB + PD = stratum basale 
and papillary dermis junction, D = dermis. AC = axisymmetric cylindrical, C = cartesian.
www.nature.com/scientificreports/
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Our results appear to agree with most other studies in the literature as discussed earlier, although it is inter-
esting to note that the diffusion coefficients calculated in this work, in human skin, are approximately one order 
of magnitude higher than in mouse skin. This difference is most likely being determined by corresponding differ-
ences in the different skins’ physical and mechanical properties. For instance, the mouse skin is more viscoelastic 
than human skin, with different cellular structures impeding diffusion34. In contrast, the more porous structure 
associated with the dermal collagen network of human skin would be expected to facilitate macromolecular dif-
fusion in the dermis, relative to that in the packed collagen matrix of mouse skin34. These findings highlight the 
importance of using human tissues in defining diffusion related to developing devices for human skin delivery of 
macromolecules, and as a minimum, a need to correct for skin structural differences when predicting their effects 
on skin permeation using animal models.
Overall, Nanopatch-delivered macromolecules were shown to diffuse through skin layers, including the per-
meation barriers of the SC and dermal-epidermal junction. Diffusivity values for the range of MWs obtained 
within this work is relevant for informing the development of skin-targeting medical devices delivering vaccines 
and drug molecules. Differences in skin diffusivity between the present work in human skin and past work in 
mouse skin clearly exist. The findings suggest there is a need for more literature data based on similar experimen-
tal methodologies to assist in both the development and the translation of these device technologies into clinical 
use.
Conclusions
Understanding and quantifying the diffusivity of macromolecules in the skin underpins the development of 
novel, microscale devices that effectively target skin delivery. We investigated macromolecule diffusion in all 
layers of ex vivo human skin through the minimally invasive application microprojection arrays to deposit RDs of 
various MWs, and imaged the skin using non-invasive MPM. We demonstrated a rapid clearance within 30 min-
utes in the skin of relatively small RDs (70 kDa), and stagnation of larger molecules (2000 kDa). Diffusivity values 
increased from the skin surface (~3–8 µm2 s−1) down to the papillary dermis (~1–20 µm2 s−1, depending on the 
model) but a significant decrease in diffusivity was observed in the dermal-epidermal junction (~0.7–3 µm2 
s−1), which would have impeded diffusion through to the dermis without direct breaching and deposition by 
the microprojections. We propose that our human skin model is the closest to in vivo conditions. Indeed, our 
minimally invasive medical device coupled with our non-invasive characterisation techniques could inform drug 
diffusivity in individuals, and permit the tailoring of nano-delivery systems for personalised medicine in the 
future. Quantifying the diffusivity properties of macromolecules for a range of MWs in human skin down to the 
individual skin stratum could provide a significant step in more accurate design and development of the fabrica-
tion, geometry and drug formulations used in these technologies.
Materials and Methods
Ethics statement. All work carried out has been approved by The University of Queensland Human 
Research Ethics Committee (approval number 2008001342). Written informed consent was obtained from all 
participants. All experiments were carried out in accordance with The University of Queensland guidelines.
Nanopatch manufacture. Solid microneedle arrays (Nanopatch) were manufactured from silicon wafers 
using the Deep Reactive-Ion Etching method53 at the Australian National Fabrication Facility – Queensland Node 
(ANFF-Q) (Brisbane, Australia) to a specification of 10,000 projections per cm2, tapered to approximately 250 µm 
in length and 40 µm base width, tapering to a cone tip of ~15°. Wafers were diced into 4 × 4 mm squares for coat-
ing and application. Nanopatch patches tilted to 45° were examined with a scanning electron microscope (SEM) 
(SU3500, Hitachi, Tokyo, Japan and JCM-5000, Jeol, Tokyo, Japan) with secondary electron detector (uncoated) 
or backscattered detector (coated/applied) at 10–15 kV.
Nanopatch coating. 70, 500 and 2000 kDa rhodamine-labelled dextrans were chosen as models of low, 
medium and high molecular weight (MW) macromolecules. The coating formulation was similar as per pre-
viously54 (for penetration depth investigation) except for replacing the FluoSpheres component with 14C (for 
delivery efficiency investigation), or RD of one MW per patch (for diffusion investigation). Patches were air-dried 
using jet-assisted airflow as per Chen et al.55.
Skin tissue collection, preparation and characterisation. Excess abdominal skin was collected from 
female patients undergoing abdominoplasty (n = 15 donors, m = 36 years old, SD = 7.8). Subcutaneous fat was 
discarded, and the skin was wrapped in aluminium foil and stored at 4 °C until the commencement of the experi-
ment (<48 h), or frozen at −20 °C and sealed airtight (>48 h). Dermatomed dermis was also prepared by remov-
ing 200 µm from the skin’s surface (Padgett Model B, Integra Lifesciences, NJ, USA). Skin specimens were allowed 
to return to room temperature (~22 °C) before the Nanopatch application. Skin used in this study was character-
ised previously34 for its physical and mechanical properties.
Experimental design. Experiments to study RD diffusivity in the SC, VE and superficial papillary dermis 
were carried out on fresh full thickness human skin, imaged from the surface to a depth of 100 µm. Four replicates 
were carried out per RD MW. Following this, we investigated diffusion in the dermal-epidermal junction, the 
rete and ridges region by applying the Nanopatch directly on to the dermis (full-thickness skin with epidermis 
removed ~200 µm from the surface with a dermatome) and imaging from the new surface to 100 µm. Three 
replicates were carried out with 500 kDa RD. Subsequently, lateral diffusion of 500 kDa RD in the dermis was 
studied by application of the Nanopatch on three skin replicates of thawed full-thickness skin. Past studies using 
carefully-handled frozen skin demonstrated suitability for drug diffusion16,56. Images were taken from a depth of 
100–200 µm.
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Nanopatch application onto skin. A simplified diagram illustrating the skin strata and microprojec-
tion penetration is shown in Fig. 1(a). Experiments were carried out at the Translational Research Institute 
(Woolloongabba QLD, Australia). To apply a Nanopatch, the skin was first placed on ten plies of 0.9% w/v 
saline-moistened (Baxter, NSW, Australia) folded Scott Compact Towels (Kimberley-Clark Australia, Milsons 
Point NSW, Australia) in a polystyrene tray (similar to Jee et al.) maintaining pH and osmolarity)57. The skin was 
held down prior to application to mimic in vivo/in situ tension. An application velocity of ~15 m s−1 was achieved 
with an in-house developed spring-loaded applicator. The patch was removed two minutes post-application to 
allow sufficient time for the coating to dissolve54. Patched skin area was immediately excised and imaged. The first 
imaged time point is approximately five minutes after the moment of patch application when the excision of skin 
and the search for a suitable area and microscope configuration were factored in.
Measurement of microprojection penetration depth and delivery efficiency. Microprojection 
penetration depth was measured using histology sectioning, as detailed by Crichton et al.54 Penetration tracks 
shown with delivered FluoSpheres were measured from the surface of the skin as the penetration depth. At least 
100 tracks in total were measured (n = 4). Delivery efficiency was used to measure the amount of vaccine eluded 
into skin versus amount remaining on the patch. The method was identical as per previous studies28. In brief, 
patches were coated with 14C-labelled ovalbumin (American Radiolabeled Chemicals, MO, USA) with 3–4 repli-
cates applied onto four skin samples each.
Cryo-SEM imaging. Representative images illustrating Nanopatch application through the skin surface were 
captured using Cryo-SEM (XL30, Philips, Amsterdam, Netherlands; JSM-7100F, JEOL, Tokyo, Japan). As previ-
ously27 and similarly58, with exceptions in brief: the Nanopatch was applied onto skin as described in Section 5.6, 
but excised with the patch in situ and adhered (Tissue-Tek OCT Compound, Sakura Finetek, Alphen aan den 
Rijn, Netherlands) onto the specimen stage. The patch remained on the skin (cross-sectional view) and fractured 
with utility pliers in liquid nitrogen or was removed (top-down view) prior to submerging. The sample was then 
sealed and transferred to the cryotransfer chamber under vacuum to prevent moisture contamination. Samples 
were iridium coated for two minutes prior to imaging and sublimated when applicable. Temperatures were set to 
−145 °C in the chamber and pre-chamber; −195 °C for the anti-contaminator and −105 °C for sublimation (over 
ten minutes). Images were captured using secondary electron detector, accelerating voltage of 2–5 kV. Images 
obtained were not post-processed except for brightness and contrast adjustment, and labelling.
Multiphoton fluorescence imaging. Multiphoton fluorescence images of patched skin were acquired 
using the LaVision Biotec Nikon Ti-U inverted microscope (Bielefeld, Germany) equipped with a 20 × 0.95 
NA water immersion lens (Olympus, Tokyo, Japan) and Titanium:Sapphire femtosecond-pulse Spectra Physics 
Mai-Tai laser (Santa Clara CA, USA). The excitation wavelength was set at 760 nm. A stack of 500 × 500 µm 
images with a pixel resolution of 1047 × 1047, along the Z-plane with a step size of 5 µm was obtained. Imaging 
power when imaged for depths between 0–100 µm was set to 14.5 mW and increased to 47 mW for depths of 
100–200 mW. Each replicate was imaged for 30 minutes.
Emitted light was separated into three channels and detected by their respective bandpass filters (410–485 nm 
(cellular auto-fluorescence); 485–550 nm (cellular auto-fluorescence and RD); and 550–670 nm (RD)), with one 
raw image stack generated per emission channel.
Multiphoton images were processed using Fiji59. The emission channels were pseudo-coloured green (λex: 
410–485 nm), blue (λex: 485–550 nm) and red (λex: 550–670 nm) and merged to form a single image stack and 
saved as.jpg images. Images from the green and red channels were saved separately in.jpg format. Space-time 
reconstruction images and videos were created using Imaris 6.3.1 (Bitplane, Belfast, United Kingdom).
Diffusion analysis. Images obtained from the 550–670 nm filter as described in Section 5.9 were first 
assessed qualitatively, then in Matlab R2016b/R2017a (MathWorks, MA, USA) for quantitative profiling – meas-
urement of the distance of RD diffusing from the centre of the hole and the associated fluorescent intensities. 
All replicates were analysed individually as a single stack, containing the entire z-plane, then repeated for all 
time points. Between four to five visible projection holes in all layers, away from flooded furrows, were selected. 
The same coordinates were also used to characterise the puncture hole aperture in images obtained from the 
410–485 nm filter. The centre of the projection hole was selected manually for all analyses. A circular area with a 
diameter of 107 µm (corresponding to equidistant spacing between projections) was chosen at the centre of each 
projection hole for diffusion analysis, and a diameter of 50 µm (slightly larger than projection size) was used for 
analysis of hole aperture to account for any relative changes in hole size over time. The centre of the area was 
chosen manually.
Two methods were developed to quantify the diffusion: a visual analysis approach looking at the maximum 
and minimum diffusion fronts of the dye in space and time to estimate clearance in Section 5.10.1 and determin-
ing the diffusivity values by comparing neighbouring pixel changes in space and time using Fick’s second law of 
diffusion in Section 5.10.3.
Assessment of the rate of spread from puncture hole centres. This is a quantitative method to determine the extent 
of the spread of RD within the skin. We calculated the mean distance (radius) from the puncture hole centre 
by applying two cut-off filters at 5% and 95% brightness threshold to quantify the spread at its maximum satu-
rated intensity and the minimum detectable intensity, respectively, using the Matlab function im2bw. These two 
cut-off values were selected to account for some of the background signal (noise) captured during the imaging 
process. Two cut-off values were used, as the initial assessment of the images showed a small region at the centre 
of projections where the intensity is fully saturated, and an outer, surrounding region where RD signal was less 
www.nature.com/scientificreports/
1 1Scientific RepoRtS |         (2018) 8:17759  | DOI:10.1038/s41598-018-36009-8
intense. The ratio between the threshold region and the circle area (Fig. 7(b,c)) was used to calculate the mean 
radius from where the molecule has spread. This information is useful because it indicates the distance travelled 
and the concentration of RD in the skin over time. The rate of spread incorporates changes (if any) in projection 
hole size over time from the auto-fluorescence channel. Maximum intensity indicates the zones with the highest 
Figure 7. Method of estimating mean diffusion radius using fluorescence thresholding to detect maximum and 
minimum detectable spread of RD. (a) Representative image of patched skin, pseudocoloured to represent RD. 
(b) Fluorescence threshold at 5%. (c) Fluorescence threshold 95%. Three to four puncture holes were selected 
for analysis; shown here are seven holes for demonstration purposes. Overlay graphics generated from Matlab 
code directly.
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concentration of RD, which is from where the molecule should diffuse. Minimum intensity provides information 
on the farthest distance to which the particle has dispersed, irrespective of concentration. The mean rate of spread 
of the maximum concentration threshold was used to estimate the time to complete clearance, when the mean 
radius in each layer reduces to zero. This data is presented in Table 1.
For this analysis, images were first converted to greyscale using Matlab function rgb2gray, and the intensity 
was normalised using the function imadjust and binarised with the function im2bw. Mean radius was then cal-
culated using the ratio between the detected area in white and the area of the full circle. A representative example 
is shown in Fig. 7. The results of all selected projections were averaged with standard deviation recorded. Results 
were plotted and analysed in GraphPad Prism 7 (GraphPad Software, CA, USA).
Extraction of intensity values for diffusion analysis. Here, we analyse the images for the diffusion coefficient 
analytically with Fick’s second law by first determining the intensity of each pixel from the projection centres. 
Similar to the previous section, the images were converted to greyscale, and their intensities were normalised. 
Fluorescence intensity was assumed approximately proportional to concentration as proposed by previous bodies 
of work, e.g. Raphael et al.25 Dada et al.60 and Mohammed et al.16. Brightness intensities (0–255) were captured 
circumferentially to the nearest pixel and concentrically at every 5 µm from the centre up to the midpoint between 
two projections, analysing at the same coordinates over depth (skin surface down to 100 µm also at 5 µm spacing) 
and time (immediately after patching for 30 mins at 2 mins spacing). Results of all selected projections were aver-
aged with standard deviation exported.
Modelling of diffusivity with Fick’s second law. Intensity values from the previous section were used to calculate 
diffusion coefficients using Fick’s second law of diffusion by quantifying the change in RD intensity at each loca-
tion over time (for a one-dimensional diffusion analysis):
∂
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where C(x, t) is the concentration of RD and is dependent on position. The intensity was first averaged along each 
circumference assuming axisymmetric spread from the projection hole centre (no dependence on the angle θ). 
Rearranging for the diffusion coefficient D and modifying for 2D Cartesian coordinates, similar to Raphael et 
al.25, yields the following equation:
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where r, z, t, ∂t refer to: radius from projection hole centre, depth from the skin surface, time and time step 
respectively. A further analysis of the same data using a more refined, 2D axisymmetric cylindrical coordinate 
system, to account for the expanding volume as the analysis moves away from the axis centre61.
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The results from the two analyses are shown in Fig. 6. Assuming neighbouring pixel intensity changes are 
small, and that intensity I is directly proportional to concentration C in 2D Cartesian and axisymmetric cylindri-
cal coordinates:
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where the numerator and denominator terms are approximated discretely (It, Ir and Iz, refer to the intensity value 
at one space-time coordinate) as follows:
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where Δt is the time step between stacks, Δr is the spacing between each circumference and Δz is the spacing 
between each z plane. For time steps, we compared adjacent time steps only, i.e. 2 & 4 mins, 4 & 6 mins, 6 & 
8 mins, etc. (not e.g. 2 & 6 mins, 2 & 8 mins). Then, the average weighted along r due to higher variance around the 
outer space of the area of interest, using the ratio:
σ
=w r z
r z
( , ) 1
( , ) (10)2
where w is the weighted average and σ2 is the variance. The weighted average uses the standard deviation (SD) 
obtained in the previous section σ=SD( )2 . Non-real numbers (NaN) are removed and replaced with zeros at 
this point. This in effect eliminates the centre of the projection holes (saturated zones) from the analysis. As dif-
fusion is a scalar quantity, all remaining numbers were made absolute to avoid potential subtraction of the diffu-
sion coefficient unintentionally when averaging in the next step. The new weighted mean diffusion coefficient is:
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⋅
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Repeating this for all time point comparisons of the same patch application/specimen, and assuming diffusiv-
ity is independent of time, all comparisons were averaged.
Diffusion analysis replicate selection. For replicates containing stacks that did not detect any RD signals, i.e. 
background noise, those planes were discarded, as they would be falsely indicating a low diffusivity value. This 
was observed in deeper layers, so approximately 15–20 µm were truncated from the analysis.
Data Availability
The datasets generated and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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